Recruiting multiethnic populations to preclinical Alzheimers disease trials-Diversity Supplement

University Of California-Irvine, Irvine CA

Investigators

Abstract

Abstract of Parent Research Project Alzheimer’s disease (AD) and related dementias (ADRD) disproportionately affect underrepresented racial and ethnic communities. The number of people with Alzheimer’s is expected to increase in the coming years, and with this an increased burden to the public health system. To alleviate this, it is important to find treatments through clinical trials that can slow disease progression, especially in diverse populations. Preclinical AD trials lack diversity, and the trial requirements of learning one’s biomarker status and needing a study partner to enroll could play a role. Our project focuses on understanding how the impact of these preclinical trial requirements, biomarker disclosure and study partner requirement, differs among racial and ethnic groups. We will use cognitive interviews to test our hypothesis that racial and ethnic groups differ in their willingness to learn biomarker status. We will also use a previously developed assessment instrument1, to assess attitudes toward the study partner requirement among diverse groups. We believe that the study partner requirement differentially affects ability/willingness to participate among racial and ethnic groups. This work will help us collect data to guide recruitment in preclinical AD trials in underrepresented groups, better understand attitudes toward biomarker disclosure during the research process and understand the differences in attitudes toward the study partner requirement so investigators can adjust to help underrepresented groups fill this role.